PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Facts Matter (May 19): Auditor Reveals Data Deleted From Election Machine Has Been Recovered

Show Me

Facts Matter (May 19): Auditor Reveals Data Deleted From Election Machine Has Been Recovered

Show Me

GOP Gubernatorial Candidate Vernon Jones Calls for ‘An Immediate Forensic Audit of the Georgia 2020 Election’

Show Me

AZ Senate Majority Whip Sonny Borrelli Shares His Observations On the Maricopa County Board of Supervisors: “They’re Very Disrespectful”

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded May 20, 2021 | Video: 47 Minutes 59 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded May 20, 2021 | Video: 48 Minutes 59 Seconds

Show Me

Afghanistan: Joint call for an immediate end to attacks against human rights defenders and need for protection and accountability

Show Me

Israeli Human Rights Group B’Tselem: Israel Is Committing War Crimes by Killing Civilians in Gaza

Show Me

Colorado to pay unemployed residents to get them to go back to work

Show Me

Biologically Male Sexual Predators Housed In Washington Female Prisons, Court Documents Show

Show Me

May 19, 2021 | Nightly News Rebroadcast | Video: 51 Minutes 49 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded May 19, 2021 | Video: 48 Minutes 32 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded May 19, 2021 | Video: 48 Minutes 15 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded May 19, 2021 | Video: 48 Minutes 59 Seconds

Show Me

The Media’s Matt Gaetz Source – Joel Greenberg – Just Pleaded Guilty to Making FALSE Pedophilia Allegations about His Opponents.

Show Me

Supreme Court Unanimously Rules Against Warrantless Gun Seizures

Show Me

Disturbing footage of Texas abduction shows alleged kidnapper taking 4-year-old

Show Me

More than 600,000 American kids ages 12 to 15 got Covid vaccines last week

Show Me

REPORT: Bill Gates Hoped Epstein Could Help Him Win Nobel Peace Prize

Show Me

Tlaib Confronts Biden on Israel, Saying Support Enables Crimes Against Palestinians

Show Me

May 18, 2021 | Nightly News Rebroadcast | Video: 53 Minutes 52 Seconds

Show Me

Biden Snatched War From the Jaws of Israel Peace Deals. Pence Explains How He Did It

Show Me

Officials Identify Slain Dallas 4-Year-Old as Cash Gernon, Suspect Being Held on $1.5 Million Bond

Show Me

Canada Will Need 75% Vaccination Before U.S. Border Reopens, Trudeau Suggests

Show Me

Amazon’s Ring Is Largest Civilian Surveillance Network U.S. Has Ever Seen + More

Show Me

Biden Wants to Surveil Soldier Social Media Pages, Use Private Firms to ‘Circumvent’ First Amendment

Show Me

AP’s Sally Buzbee Mired in Scandal as She Preps for Role as Washington Post Executive Editor

Show Me

Amnesty International wins Webby Award for multimedia tear gas project

Show Me

Arizona Senate Hearing on Maricopa County Audit and 2020 Election Issues – 4:00pm ET Livestream Links

Show Me

Michigan Judge Dismisses Antrim County Election Case

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded May 18, 2021 | Video: 48 Minutes 37 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded May 18, 2021 | Video: 48 Minutes 30 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 3 | Recorded May 18, 2021 | Video: 47 Minutes 58 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded May 18, 2021 | Video: 48 Minutes 58 Seconds

Show Me

May 17, 2021 | Nightly News Rebroadcast | Video: 53 Minutes 52 Seconds

Show Me

White House Defends ‘Quiet’ Diplomacy in Israel-Gaza Crisis

Show Me

Exclusive – Former Israeli Ambassador to U.N.: ‘I Would Expect from AP to Check Who Your Neighbors Are,’ IDF Warned Them Before Strike

Show Me

Parler Names George Farmer as CEO as It Returns to Apple’s App Store

Show Me

Arrest Made After Boy, 4, Found Slain on Dallas Street

Show Me

EXCLUSIVE: Republican ‘Team Effort’ Killed Bill To Stop Child Transgender Surgeries, ‘Texas GOP Needs A Housecleaning’

Show Me